Livmarli Maralixibat Application Scope

Livmarli (Maralixibat) is primarily used for the treatment of Alagille syndrome, a rare genetic disorder that affects multiple organ systems, including the liver, heart, and kidneys.

It is specifically indicated for cholestatic pruritus in patients with Alagille syndrome. By inhibiting the intestinal bile acid transporter, Maralixibat helps reduce bile acid buildup in the liver and bloodstream, thereby alleviating symptoms associated with cholestasis and improving quality of life.

Livmarli Maralixibat Characteristics

Ingredients:
- Active Ingredient: Maralixibat
- Excipients: Includes inactive ingredients such as glycerin, polysorbate, and others as stabilizers.
Properties:Maralixibat is a selective inhibitor of the ileal bile acid transporter (IBAT). It helps to reduce the amount of bile acids that are absorbed back into the bloodstream, which helps to reduce symptoms of cholestasis such as itching (pruritus) and prevent liver damage.
Specification:Available as an oral suspension, typically in 2 mg/mL concentration.
Storage:Store at room temperature (between 15°C to 30°C). Protect from light and keep the cap tightly closed.
Expiry Date:Typically has a shelf life of 24 months. Please refer to packaging for exact expiry dates.
Executive Standard:Meets regulatory standards as defined by FDA or other health authorities.
Approval Number:Specific approval details from FDA or EMA.
Manufacturer:Manufactured by Mirum Pharmaceuticals.

Guidelines For The Use Of Livmarli Maralixibat

Dosage and Administration:

The usual starting dose for Alagille syndrome patients is 0.5 mg/kg of body weight, taken once daily.
Dosage may be adjusted based on response and tolerability, up to a maximum of 1 mg/kg per day.

Adverse Reactions:

Common side effects include diarrhea, vomiting, abdominal pain, and increased liver enzymes.
Serious side effects may include liver injury or electrolyte imbalances, though these are rare.

Medication Limitations

Contraindications:

Contraindicated in patients with hypersensitivity to Maralixibat or any of the ingredients in the formulation.
Not recommended for use in patients with severe liver dysfunction.

Precautions:

Use with caution in patients with gastrointestinal disorders and renal impairment.
Regular monitoring of liver function tests and electrolyte levels is recommended during treatment.

Livmarli Maralixibat Interactions

Drug Interactions:No significant interactions have been noted with other drugs; however, caution should be taken when combining Maralixibat with drugs that affect liver function or bile flow, such as ursodeoxycholic acid or bile acid sequestrants.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine, China Drug Import and Export Wholesaler.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.